Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 986
Out of 4,829 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $41.72 | +0.67% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $181.88 | +106.18% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $82.26 | +39.80% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $95.75 | -3.92% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $17.07 | -29.70% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $11.64 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $33.92 | +165.33% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $226.43 | +19.24% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $89.96 | -24.41% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $12.65 | +255.73% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $125.11 | +119.81% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $19.42 | +90.53% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $84.67 | -29.14% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $102.86 | -65.97% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $310.67 | -73.93% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $41.72
Upside: +0.67%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $181.88
Upside: +106.18%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $82.26
Upside: +39.80%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $95.75
Upside: -3.92%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $17.07
Upside: -29.70%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $11.64
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $33.92
Upside: +165.33%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $226.43
Upside: +19.24%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $89.96
Upside: -24.41%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $12.65
Upside: +255.73%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $125.11
Upside: +119.81%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $19.42
Upside: +90.53%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $84.67
Upside: -29.14%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $102.86
Upside: -65.97%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $310.67
Upside: -73.93%